Open-label Safety and Pharmacokinetic Study of DUEXIS® (Ibuprofen and Famotidine) Tablets in Juvenile Idiopathic Arthritis

Inclusion Criteria

• Patient and guardian are willing to consent to undergo up to 24 weeks of treatment with DUEXIS (ibuprofen 800 mg/famotidine 26.6 mg) oral tablet three times daily.
• Patient is male or female, aged 10 years to 16 years, 11 months.
• Patient is diagnosed with JIA for > 1 month including oligoarthritis, polyarthritis rheumatoid factor (RF) +, polyarthritis RF-, psoriatic arthritis, enthesitis-related arthritis, or undifferentiated and systemic arthritis without systemic features in the past 6 months.
• Patient must have currently active articular disease as defined by > 1 active joint (i.e., presence of swelling, or if no swelling is present, limitation of motion [LOM] accompanied by pain, tenderness, or both).
• Based upon investigator judgment, given current treatment patient is receiving and level of disease activity, it is determined appropriate for the patient to undergo up to 24 weeks of treatment with DUEXIS (ibuprofen 800 mg/famotidine 26.6 mg) oral tablet three times daily. The investigator will use his/her clinical judgment in determining the duration of treatment for the patient based on the standard of care up to 24 weeks of treatment.
• Weight > 48 kg and body mass index (BMI) > 5th percentile using the Centers for Disease Control (CDC) BMI percentile calculator for child and teen at the screening visit.
• Patient is able to swallow a DUEXIS tablet whole.
• For the single dose pharmacokinetic (PK) subset, patients and guardians must be willing to participate in the serial blood sample collections at Day 0 and Week 4.
• Female patients of childbearing potential and male patients must agree to use medically acceptable methods of contraception, including abstinence, throughout the entire study period.
• Patient is willing and able to comply with the prescribed treatment protocol and evaluations.

Exclusion Criteria

• Patient has a history of or experienced any of the following:
• NSAID-associated and/or primary peptic ulcer disease-associated serious gastrointestinal complications such as perforation of ulcers, gastric outlet obstruction due to ulcers, and/or acute gastrointestinal bleeding
• NSAID-induced asthma exacerbation, acute renal failure, interstitial nephritis, and/or hepatitis
• Malignant disease of the gastrointestinal tract
• Erosive esophagitis
• Coronary artery bypass graft (CABG) surgery within the 14 days prior to study Day 0
• Uncontrolled diabetes mellitus as evidenced by Hemoglobin A1c > 7%
• Known history of human immunodeficiency virus (HIV), hepatitis B, and/or hepatitis C.
• Current symptoms of severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, pulmonary, cardiac, neurological, or cerebral disease.
• JIA disease is severe as defined by either physician's or parent's global assessments > 90 on a 100 point scale.
• Systemic JIA with any of the following manifestations within the last 6 months prior to enrollment: intermittent fever due to JIA, rheumatoid rash, hepatosplenomegaly, pleuritis, pericarditis, or macrophage activation syndrome.
• Active uveitis.
• Presence of any other rheumatic disease or major chronic infectious, inflammatory, immunologic disease (e.g., inflammatory bowel disease, hypogammaglobulinemia, or systemic lupus erythematosus, etc.).
• Presence at screening or history of any disease other than JIA that requires the use of chronic systemic corticosteroids.
• History of clinically significant drug or alcohol abuse.
• Presence at screening of any of the following laboratory values:
• Hemoglobin 1.5 times upper limit of normal
• Serum ALT or AST > 2.0 times upper limit of normal
• H. pylori positive
• Any other lab value that in the opinion of the investigator might place the patient at unacceptable risk for participation in this study.
• Methotrexate > 20 mg/M^2/week or > 40 mg/week.
• Patient currently is participating in an investigational drug study, or patient participated in an investigati